Skip to main content
Roche Holding AG logo

Roche Holding AG — Investor Relations & Filings

Ticker · RO ISIN · CH0012032048 LEI · 549300U41AUUVOAAOB37 SW Manufacturing
Open in API
Filings indexed 42 across all filing types
Latest filing 2026-02-03 Annual Report
Country CH Switzerland
Listing SW RO

About Roche Holding AG

https://www.roche.com/

Roche Holding AG is a global healthcare company focused on advancing science to improve health outcomes. The company operates through two primary divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals division discovers, develops, and manufactures innovative medicines across major therapeutic areas, including oncology, immunology, infectious diseases, ophthalmology, and neuroscience. The Diagnostics division provides a comprehensive portfolio of in-vitro diagnostic tests, instruments, and digital solutions that aid in the prevention, diagnosis, and monitoring of diseases. By combining its strengths in both pharmaceuticals and diagnostics, Roche aims to deliver personalized healthcare solutions that address unmet medical needs for patients worldwide.

Recent filings

Filing Released Lang Actions
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
Annual Report Classification · 95% confidence The document is a German 'Jahresabschluss' (Annual Financial Statement) for Roche Pharma Aktiengesellschaft for the fiscal year 2024. It includes a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and detailed notes (Anhang). While it is an annual report, in the context of German corporate filings, this specific structure represents the statutory annual financial report. Given the options provided, '10-K' is the standard classification for a comprehensive annual report containing financial statements and analysis. FY 2024
2026-02-03 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Interim / Quarterly Report Classification · 95% confidence The document is a formal 'Jahresabschluss' (Annual Financial Statement) for Roche Pharma Aktiengesellschaft for the fiscal year 2023. It includes a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and detailed notes (Anhang) prepared in accordance with the German Commercial Code (HGB). While it is a financial report, it is a standalone statutory financial statement for a specific subsidiary rather than a consolidated group 10-K. Given the provided categories, 'IR' (Interim / Quarterly Report) is often used for comprehensive financial reports, but since this is a full annual statutory report, it fits best under the 'IR' category as a comprehensive financial report for a specific period, or potentially 'RNS' as a regulatory filing. However, following the instruction to classify comprehensive financial reports as 'IR', this is the most accurate fit. FY 2023
2025-02-11 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Audit Report / Information Classification · 98% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Roche mtm laboratories AG for the fiscal year ending December 31, 2023. It contains a balance sheet (Bilanz), profit and loss account details, and notes (Anhang) prepared in accordance with German commercial law (HGB). While it is a standalone financial report, it functions as the company's annual financial reporting document. Given the specific categories provided, '10-K' is the most appropriate classification for a comprehensive annual financial report, even for a non-US entity, as it represents the official yearly financial performance report. FY 2023
2025-01-21 German
Bericht zur Gleichstellung und Entgeltgleichheit nach EntgTranspG als Anlage des Lageberichts zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Environmental & Social Information Classification · 95% confidence The document is a report on equality and pay equity ('Bericht zur Gleichstellung und Entgeltgleichheit') as required by the German Transparency Act (EntgTranspG). It details statistical data on gender distribution and specific measures taken by the company to promote equality and ensure equal pay. This content falls under Environmental, Social, and Governance (ESG) reporting, specifically the 'Social' aspect regarding workforce diversity and fair compensation practices. Therefore, it is classified as an Environmental & Social Information report.
2024-02-28 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Audit Report / Information Classification · 98% confidence The document is a comprehensive financial report for Roche Pharma Aktiengesellschaft for the fiscal year 2022. It includes a balance sheet (Bilanz), profit and loss statement (Gewinn- und Verlustrechnung), and detailed notes (Anhang) explaining accounting methods and specific line items. This structure is characteristic of a statutory annual financial report (Jahresabschluss) under German HGB (Handelsgesetzbuch) regulations. While it is a component of the annual reporting cycle, it represents the full financial disclosure for the year rather than a summary or an announcement. FY 2022
2024-02-14 German
Jahresabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
Annual Report Classification · 95% confidence The document is a 'Jahresabschluss' (Annual Financial Statement) for Roche mtm laboratories AG for the fiscal year ending December 31, 2022. It contains a balance sheet (Bilanz), notes to the financial statements (Anhang), and details on assets and liabilities. While it is a subsidiary report, it constitutes the official annual financial reporting for the entity, which aligns with the definition of an Annual Report (10-K) in the context of corporate filings. FY 2022
2024-01-05 German

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.